Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
5.42
+0.11 (2.07%)
At close: Dec 5, 2025, 4:00 PM EST
5.38
-0.04 (-0.74%)
After-hours: Dec 5, 2025, 4:04 PM EST
Bolt Biotherapeutics Revenue
Bolt Biotherapeutics had revenue of $2.17M in the quarter ending September 30, 2025, with 90.10% growth. This brings the company's revenue in the last twelve months to $5.20M, down -46.88% year-over-year. In the year 2024, Bolt Biotherapeutics had annual revenue of $7.69M, down -2.36%.
Revenue (ttm)
$5.20M
Revenue Growth
-46.88%
P/S Ratio
2.00
Revenue / Employee
$99,904
Employees
52
Market Cap
10.40M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BOLT News
- 23 days ago - Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 - GlobeNewsWire
- 4 months ago - Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - GlobeNewsWire
- 8 months ago - Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 9 months ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire